Zinc Transporters: New Insights For Cancer Therapy | 3528
Journal of Gastrointestinal & Digestive System
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Pancreatic cancer is the number one cancer killer with 5-year survival less than 5%. It is urgently needed to identify novel
molecular markers and therapeutic targets in pancreatic cancer that could lead to more effective treatment for this deadly
disease. Our recent study suggests that a dietary zinc transporter, ZIP4, is over expressed in pancreatic cancer and brain tumor,
and promotes cancer growth and metastasis. Those results indicate that ZIP4 and zinc transport pathway is a novel therapeutic
target for cancers. Our results also suggest that ZIP4 can serve as a cancer master switch gene to impact the downstream signaling
pathways including cytokines, microRNAs, and transcriptional factors.
Min Li got his Ph.D. from Emory University in 2002. He then moved on to Baylor College of Medicine and started his career in cancer research
as an Assistant Professor in 2004. He joined the University of Texas Health Science Center at Houston, Medical School in 2010 as the Director of
Cancer Research Program. His research interests include pancreatic cancer and brain tumor. Dr. Li's group is the first one to identify ZIP4 as a novel
molecular target in pancreatic cancer. He has published more than 100 papers and serves as an editorial board member of many peer reviewed
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals